Definium Therapeutics Inc (DFTX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access DFTX Annual Balance Sheets →
From Definium Therapeutics Inc through Mar 31 2025, shifts in Mar 31 2026's assets and liabilities provide insight into the company's capital structure and financial stability.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent262.52
Short-term Investments, Total110.90
Cash & Short-term Investments372.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current7.14
Total Current Assets380.56
Goodwill net19.92
Long-term investments0.00
Other Assets, Noncurrent0.81
Total Assets401.29
Liabilities
Accounts Payable, Current AC7.13
Accrued Liabilities, Current AC24.51
Total Current Liabilities81.11
Long-term debt40.77
Total Long-term Debt40.77
Other liabilities, Noncurrent50.03
Financing Warrants Liability49.47
Total Liabilities122.44
Stockholders' Equity
Additional Paid In Capital Common Stock937.80
Retained Earnings / Accumulated Deficit-659.77
Other Equity0.82
Common Stockholder's Equity278.85
Total Stockholder's Equity278.85
Liabilities & Stockholder's Equity401.29
4 historic quarters locked

Sign in to unlock the full Definium Therapeutics Inc balance sheet history.

About Definium Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-338066

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.